Vimukthini Peiris

21st #AnnualAcedemicSessions of @slconcology kicks off to an auspicious start! @hiprabs @sidathwijeseke1

Have u ever seen curves as wide as this for any drug recently? Lorlatinib for metastatic ALK positive NSCLC. Great results 👏. It works With reduced dose also. Let's hope it becomes more accessible. @asco #asco24 @OncoAlert @OncBrothers @Larvol @Alfdoc2 @JackWestMD @brunolarvol

WOW! HPV ctDNA detection at 3 months after dCRT for anal canal cancer associated with 100% risk of recurrence! 8% with HPV ctDNA negative #ASCO24

MONARCH 3: Final overall survival results 🔍mFU: 8.1 years (OS: secondary endpoint) mOS➡️66.8 vs 53.7 mo (HR:0.8, p:0.06) 💥The absolute difference was 13.1 months but did not reach statistical significance @Annals_Oncology @OncoAlert annalsofoncology.org/article/S0923-…

The standard of care for stage III NSCLC changes once again; Say goodbye to Durvalumab for patients with mEGFR (ex19del & L858R). #radonc astrazeneca.com/media-centre/p…

TiP: EA8211-SOAR: Non-inferiority phase 3 trial of SABR vs systemic therapy for metachronous (pre-treated) oligometastatic RCC (2-5 mets, IMDC fav-int risk) 🔷SABR arm: Systemic therapy only following progression 🔷Co-primary: OS & Gr≥3 toxicity 🔷Secondary: QoL, PFS, cost-effectiveness, ctDNA correlatives @urotoday #GU24

1/N Finally out!! -- 30Gy for HPV+OPC in @JCO_ASCO – work by the @MSKCancerCenter Head and Neck team, led by @imrtlee, Eric Sherman, and myself on using hypoxia imaging response to cut treatment 60% (70->30Gy)! #radonc #hncsm ascopubs.org/doi/10.1200/JC…

✨Join us at NCISL where a star studded cast will discuss the latest advancements in #Oncology organised by the @CSSL_AAS and @slconcology in collaboration with @TataMemorial Centre #India✨ 24th January 2024. @prasaday @Dr_Pawan_Rane @Shrikhande_SV

In Sri Lanka there's this massive column of rock nearly 200 m high that hosts a 1600-year-old fortress on its top [read more: buff.ly/48g9IVX]

Wishing you a year filled with strength, resilience, and healing. Happy New Year! #NewYear #2024NewYear

COLOMBO....🇱🇰 📸 @ThilinaKalu

Testicular cancer in 2023- a good review acsjournals.onlinelibrary.wiley.com/doi/full/10.33……

📌Watch our eminent consultant oncologist @nuradh speak on #breastcancer 🇱🇰 #BreastCancerAwareness @adaderana fb.watch/o63KIjHROj/

"No matter what obstacles we encounter, we owe it to our patients not to allow the high standards we have upheld thus far, to diminish. Therefore, excellence should remain our ultimate goal in all that we do" Inspiring words by #SLCO president @prasaday sundaytimes.lk/231029/news/im…

Honoured to have been given the #opportunity be a part of the 4th batch of #LeadershipDevelopment program of @faro_asia. Thank you #FARO and @slconcology!

I've used this widely in my practice due to resource constraints with excellent results.. #hypofractionation #headandneckcancer @slconcology @slcancer @Vimukthini

Twice daily radiotherapy to 54Gy BID ⬆️⬆️ OS and PFS in small cell #lungcancer as compared to 45Gy BID. compared to CONVERT and RTOG, higher once daily RT did not ⬆️ OS. #lcsm - abstract ➡️ shorturl.at/huDJ2 - time to change?

This is absolutely brilliant. Not only is the data compelling, @_ShankarSiva, but it is presented in a manner that I feel may be quite conducive to sharing with my patients for discussion (thoughts, @LauraEsfeller @DebMaskens @RCCadvocate @advocatekidneys?). Your talk at #ASTRO23 not only validates a terrific option for pts 👏 but could provide all of us in academics a better way to practically convey information.

October is #BreastCancer #Awareness month. The commonest cancer among women in #SriLanka it is eminently curable if detected early. @SlCancer @indira_trust #lka

🌟 Discover the Future of Oncology at SLCO Annual Academic Sessions 2023! 🌟 📅 October 13th - 15th, 2023. 🏨 Hotel Galadari, Colombo. Visit slco.lk for registration! #SLCOnc2023 #OncologyConference